hCAI/II-IN-6 是一种具有口服活性的 human carbonic anhydrase (CA) 抑制剂。hCAI/II-IN-6 选择性地抑制 hCA II 和 hCA VII，对 hCA I，hCA II，hCA VII 和 hCA XII 的 Ki 值分别为 220，4.9，6.5 和 ＞50000 nM。hCAI/II-IN-6 在体内显示抗惊厥活性和抗最大电击 (MES) 活性。hCAI/II-IN-6 可以用于癫痫的研究。
| Cas No. | 694466-00-7 |
| 分子式 | C19H24N4O3S |
| 分子量 | 388.48 |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | hCAI/II-IN-6 is an orally activehuman carbonic anhydrase(CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms withKivalues of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy[1]. hCAI/II-IN-6 (0-50 μM) inhibits hCA I, hCA II , hCA VII and hCA XII activities withKivalues of 220, 4.9, 6.5 and ＞50000 nM, respectively[1]. hCAI/II-IN-6 (30-100mg/kg; i.p. once) shows good anticonvulsant effect in vivo[1].
hCAI/II-IN-6 (30 mg/kg; p.o. once) shows anti-MES activity in vivo[1]. | Animal Model: | Swiss albino mice[1] | | Dosage: | 30 and 100 mg/kg | | Administration: | Intraperitoneal injection; 30-100 mg/kg once | | Result: | Provided seizure attenuation and good anticonvulsant effect, and showed an ED50of 13.7mg/kg in anticonvulsant quantification study. |
| Animal Model: | Wistar albino rats[1] | | Dosage: | 30 mg/kg | | Administration: | Oral gavage; 30 mg/kg once | | Result: | Showed anti-MES activity and significant protection from seizures up to 1h of drug administration and action was gone reduced after 1h. |
|
